# Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane

> **NCT07517289** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Egyptian International Pharmaceutical Industries Co** · enrollment: 26 (estimated)

## Conditions studied

- Healthy Participants Study
- The Focus of the Study is to Determine the Comparative Pharmacodynamic of Enoxaparin Sodium With That of Clexane in Healthy Human Participants

## Interventions

- **BIOLOGICAL:** Enoxaparin 40 Mg/0.4 mL Injectable Solution

## Key facts

- **NCT ID:** NCT07517289
- **Lead sponsor:** Egyptian International Pharmaceutical Industries Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-30
- **Primary completion:** 2026-06
- **Final completion:** 2026-08
- **Target enrollment:** 26 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07517289

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07517289, "Study to Determine the Comparative Pharmacodynamics of Enoxaparin Sodium Biosimilar With That From Clexane". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07517289. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*